Rodriguez-Pardo, DolorsDel -Toro, Maria DoloresGuio-Carrion, LauraEscudero-Sanchez, RosaFernandez-Sampedro, MartaGarcia-Viejo, Miguel AngelVelasco-Arribas, MariaSoldevila-Boixader, LauraFemenias, MagdalenaIribarren, Jose AntonioPulido-Garcia, Maria Del CarmenNavarro, Maria DoloresLung, MayliCorona, Pablo SAlmirante, BenitoPigrau, Carles2023-02-092023-02-092021-11Rodríguez-Pardo D, Del Toro MD, Guío-Carrión L, Escudero-Sánchez R, Fernández-Sampedro M, García-Viejo MÁ, et al. Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial. Eur J Clin Microbiol Infect Dis. 2021 Nov;40(11):2411-2419.http://hdl.handle.net/10668/17592To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture. Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. early-PJI after HHA. Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33-3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15-7.10]). Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47.enAsymptomatic bacteriuriaEarly-periprosthetic joint infectionFosfomycin-trometamolHip hemiarthroplastyAgedAged, 80 and overAnti-Bacterial AgentsArthroplasty, Replacement, HipAsymptomatic InfectionsBacteriuriaFemaleFosfomycinHumansJoint DiseasesMaleProsthesis-Related InfectionsTromethaminereport33864153Restricted AccessTrometaminaFosfomicinaBacteriuriaHemiartroplastiaPérdida de pesoIncidencia10.1007/s10096-021-04241-21435-4373https://www.researchsquare.com/article/rs-203528/v1.pdf?c=1631892207000